CMEonHIV.com is dedicated to providing online CME presentations (slides with voiceover) on HIV/AIDS for healthcare professionals given by local and international experts to keep you up-to-date on the ongoing developments in the field.
Biography
Carlos Zala
Carlos Zala, MD
Fundacion Hueped
Angel Peluffo 3932
1202 Buenos Aires
Argentina
Current Position
Director, Clinical Research
Fundacion Huesped
Buenos Aires, Argentina
Primary Area of Interest
Antiretroviral Therapy
Medical Training
University of Buenos Aires. Argentina
Degree: Medical Doctor (1984)
Post Doctoral Fellowship
HIV/AIDS Research Program
St Paulīs Hospital (1994-1997)
Recent Publications
C Zala, H Salomon, C Ochoa, G Kijak, A Federico, H Perez, JSG Montaner, P Cahn
Higher rate of toxicity with no increased efficacy when Hydroxyurea is added to a regimen of satuvudine plus didanosine and nevirapine in primary HIV infection
Journal of Acquired Immnodeficiency Syndromes, 2002; 29: 368-373
G Kijak, V Simon, P Balfe, J Vanderhoeven, S Pampuro, C Zala, C Ochoa, P Cahn, M Markowitz, H Salomon
Origin of Human Immunodeficiency Virus Type 1 quasicspecies emerging after antiretroviral treatemen interruptionin patients with therapeutic failure.
Journal of Virology, 2002; 79 (14): 7000-7009
G Kijak, S Pampuro, M Avila, C Zala, P Cahn, M Wainberg, H Salomon
Resistance profiles to antiretroviral drugs in HIV-1 drug naive patients in Argentina
Antiviral Therapy, 2001; 6 (1):71-7
C Zala, C Ochoa, A Krolewiecki y col.,
Highly active antiretroviral therapy does not protect against Kaposiīs sarcoma in HIV-infected individuals
AIDS 2000, 14:2217-18
C Zala, D Rouleau, JSG Montaner.
The role of hydroxyurea in the treatment of HIV disease
Clinical of Infectious Diseases 2000 30 (Suppl2): S143-15
List of presentations from this healthcare provider available on CMEonHIV :
USER ACKNOWLEDGES AND AGREES THAT ALL DECISIONS MADE WITH THE ASSISTANCE OR USE OF THE SOFTWARE AND/OR THE WEBSITE AND/OR BASED ON CONTENT FOUND HEREIN WILL BE EXCLUSIVELY THE RESPONSIBILITY OF THE USER.
